Endocrine Abstracts

Bone loss is a frequent complication of aromatase inhibitors (AIs) therapy in women with breast cancer. Bone-active drugs are effective in protecting the skeleton from detrimental actions of AIs. However, bone mineral density (BMD) was the primary end-point in most of published studies, whereas data on fractures were scant and mainly limited to denosumab. In this prospective study, we investigated the effects of denosumab, oral bisphosphonates and intravenous zoledronate on ri...

Background: Skeletal fragility is an important clinical issue in women with early-stage breast cancer and men with non-metastatic prostate cancer under hormonal hormone deprivation therapies (HDTs). Vertebral fractures (VFs) have been reported in a remarkable number of subjects exposed to HDT especially when the diagnosis of fractures is performed by a radiological and morphometric approach. Notably, prediction of fractures in this clinical setting is a challenge and determina...

Introduction: Bone mineral density (BMD) is considered a valid surrogate of bone strength in postmenopausal women, however it lacks sensitivity in individual fracture risk assessment in the setting of women with early breast cancer (EBC) patients treated with aromatase inhibitors (AIs). Indeed, mechanical resistance of bone only partially depends on bone quantity, and bone geometry and size play an important role in bone resistance to fractures. In this cross-sectional study, ...